The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions
Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone immunochemotherapy remains standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). High-dose chemotherapy and stem cell transplantation is offered to most relapsing/refractory patients who respond to sa...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2019-01, Vol.15 (3), p.305-317 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 317 |
|---|---|
| container_issue | 3 |
| container_start_page | 305 |
| container_title | Future oncology (London, England) |
| container_volume | 15 |
| creator | Jurczak, Wojciech D ugosz-Danecka, Monika Rivas Navarro, Fernando |
| description | Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone immunochemotherapy remains standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). High-dose chemotherapy and stem cell transplantation is offered to most relapsing/refractory patients who respond to salvage therapy. This Q&A review evaluates recommended management strategies for second and subsequent lines of therapy in patients with DLBCL, outlining the relative efficacies of currently available options including novel agents such as ibrutinib and CAR-T cells. The combination of pixantrone and rituximab is currently under investigation as a second-line treatment for patients ineligible for stem cell transplantation, while pixantrone monotherapy is the only therapeutic option approved for multiply relapsed and refractory DLBCL beyond the second line at this time. |
| doi_str_mv | 10.2217/fon-2018-0388 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2116125830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216536462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-4876b7d26d04637c41a087ff76857c0dcf2b0d168d29f6503b8c8c58a53f39113</originalsourceid><addsrcrecordid>eNp1kU1PHSEYhUmjqdZ22a0hceMG5WuAcadGq4lJN3Y9YRi4FzsDI8zU3H8vc692YeIKOHk475tzAPhJ8BmlRJ67GBDFRCHMlPoCDonkHCmGyV65c1kjIWp-AL7l_IQxl6zCX8EBw1ThmvJD0D-uLUx68jHo3kIXEzRxaH3YSnBa26THDfQBjkWxYcrwxU9rqFerZHP2_yy8Qsb2PQxlkbvYrf4Wtt8M4zoO-gJONsDn2ebFLX8H-0732f54O4_An9ubx-s79PD71_315QMynOAJcSVFKzsqOswFk0XUWEnnpFCVNLgzjra4I0J1tHaiwqxVRplK6Yo5VhPCjsDpzndMcTu8GXxeltTBxjk3lBBBaFVSKujJB_QpzqlkUShKRMUEF7RQaEeZFHNO1jVj8oNOm4bghZNNqaFZamiWGgp__OY6t4Pt_tPvuReg3gFunuYSpCnRGtvsXuWHNz7YT8xfAVj4lpk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216536462</pqid></control><display><type>article</type><title>The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions</title><source>MEDLINE</source><source>PubMed Central</source><creator>Jurczak, Wojciech ; D ugosz-Danecka, Monika ; Rivas Navarro, Fernando</creator><creatorcontrib>Jurczak, Wojciech ; D ugosz-Danecka, Monika ; Rivas Navarro, Fernando</creatorcontrib><description>Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone immunochemotherapy remains standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). High-dose chemotherapy and stem cell transplantation is offered to most relapsing/refractory patients who respond to salvage therapy. This Q&A review evaluates recommended management strategies for second and subsequent lines of therapy in patients with DLBCL, outlining the relative efficacies of currently available options including novel agents such as ibrutinib and CAR-T cells. The combination of pixantrone and rituximab is currently under investigation as a second-line treatment for patients ineligible for stem cell transplantation, while pixantrone monotherapy is the only therapeutic option approved for multiply relapsed and refractory DLBCL beyond the second line at this time.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2018-0388</identifier><identifier>PMID: 30280924</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer therapies ; Canellos, George ; CAR-T cells ; Chemotherapy ; Clinical trials ; Combined Modality Therapy ; diffuse large B-cell lymphoma ; Gene expression ; Humans ; ibrutinib ; Immunotherapy, Adoptive ; Isoquinolines - therapeutic use ; Leukemia ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphoma, Large B-Cell, Diffuse - therapy ; Lymphoma, Non-Hodgkin - pathology ; Lymphoma, Non-Hodgkin - therapy ; Medical imaging ; Medical prognosis ; Monoclonal antibodies ; Participation ; Patients ; pixantrone ; Pyrazoles - therapeutic use ; Pyrimidines - therapeutic use ; Rituximab - therapeutic use ; Salvage Therapy ; second-line treatment ; Stem Cell Transplantation ; Studies ; Systematic review ; Targeted cancer therapy ; Young, Robert</subject><ispartof>Future oncology (London, England), 2019-01, Vol.15 (3), p.305-317</ispartof><rights>2018 The Authors</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-4876b7d26d04637c41a087ff76857c0dcf2b0d168d29f6503b8c8c58a53f39113</citedby><cites>FETCH-LOGICAL-c410t-4876b7d26d04637c41a087ff76857c0dcf2b0d168d29f6503b8c8c58a53f39113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30280924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jurczak, Wojciech</creatorcontrib><creatorcontrib>D ugosz-Danecka, Monika</creatorcontrib><creatorcontrib>Rivas Navarro, Fernando</creatorcontrib><title>The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone immunochemotherapy remains standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). High-dose chemotherapy and stem cell transplantation is offered to most relapsing/refractory patients who respond to salvage therapy. This Q&A review evaluates recommended management strategies for second and subsequent lines of therapy in patients with DLBCL, outlining the relative efficacies of currently available options including novel agents such as ibrutinib and CAR-T cells. The combination of pixantrone and rituximab is currently under investigation as a second-line treatment for patients ineligible for stem cell transplantation, while pixantrone monotherapy is the only therapeutic option approved for multiply relapsed and refractory DLBCL beyond the second line at this time.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer therapies</subject><subject>Canellos, George</subject><subject>CAR-T cells</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>diffuse large B-cell lymphoma</subject><subject>Gene expression</subject><subject>Humans</subject><subject>ibrutinib</subject><subject>Immunotherapy, Adoptive</subject><subject>Isoquinolines - therapeutic use</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Lymphoma, Large B-Cell, Diffuse - therapy</subject><subject>Lymphoma, Non-Hodgkin - pathology</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Monoclonal antibodies</subject><subject>Participation</subject><subject>Patients</subject><subject>pixantrone</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Rituximab - therapeutic use</subject><subject>Salvage Therapy</subject><subject>second-line treatment</subject><subject>Stem Cell Transplantation</subject><subject>Studies</subject><subject>Systematic review</subject><subject>Targeted cancer therapy</subject><subject>Young, Robert</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU1PHSEYhUmjqdZ22a0hceMG5WuAcadGq4lJN3Y9YRi4FzsDI8zU3H8vc692YeIKOHk475tzAPhJ8BmlRJ67GBDFRCHMlPoCDonkHCmGyV65c1kjIWp-AL7l_IQxl6zCX8EBw1ThmvJD0D-uLUx68jHo3kIXEzRxaH3YSnBa26THDfQBjkWxYcrwxU9rqFerZHP2_yy8Qsb2PQxlkbvYrf4Wtt8M4zoO-gJONsDn2ebFLX8H-0732f54O4_An9ubx-s79PD71_315QMynOAJcSVFKzsqOswFk0XUWEnnpFCVNLgzjra4I0J1tHaiwqxVRplK6Yo5VhPCjsDpzndMcTu8GXxeltTBxjk3lBBBaFVSKujJB_QpzqlkUShKRMUEF7RQaEeZFHNO1jVj8oNOm4bghZNNqaFZamiWGgp__OY6t4Pt_tPvuReg3gFunuYSpCnRGtvsXuWHNz7YT8xfAVj4lpk</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Jurczak, Wojciech</creator><creator>D ugosz-Danecka, Monika</creator><creator>Rivas Navarro, Fernando</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190101</creationdate><title>The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions</title><author>Jurczak, Wojciech ; D ugosz-Danecka, Monika ; Rivas Navarro, Fernando</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-4876b7d26d04637c41a087ff76857c0dcf2b0d168d29f6503b8c8c58a53f39113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer therapies</topic><topic>Canellos, George</topic><topic>CAR-T cells</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>diffuse large B-cell lymphoma</topic><topic>Gene expression</topic><topic>Humans</topic><topic>ibrutinib</topic><topic>Immunotherapy, Adoptive</topic><topic>Isoquinolines - therapeutic use</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Lymphoma, Large B-Cell, Diffuse - therapy</topic><topic>Lymphoma, Non-Hodgkin - pathology</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Monoclonal antibodies</topic><topic>Participation</topic><topic>Patients</topic><topic>pixantrone</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Rituximab - therapeutic use</topic><topic>Salvage Therapy</topic><topic>second-line treatment</topic><topic>Stem Cell Transplantation</topic><topic>Studies</topic><topic>Systematic review</topic><topic>Targeted cancer therapy</topic><topic>Young, Robert</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jurczak, Wojciech</creatorcontrib><creatorcontrib>D ugosz-Danecka, Monika</creatorcontrib><creatorcontrib>Rivas Navarro, Fernando</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jurczak, Wojciech</au><au>D ugosz-Danecka, Monika</au><au>Rivas Navarro, Fernando</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>15</volume><issue>3</issue><spage>305</spage><epage>317</epage><pages>305-317</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone immunochemotherapy remains standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). High-dose chemotherapy and stem cell transplantation is offered to most relapsing/refractory patients who respond to salvage therapy. This Q&A review evaluates recommended management strategies for second and subsequent lines of therapy in patients with DLBCL, outlining the relative efficacies of currently available options including novel agents such as ibrutinib and CAR-T cells. The combination of pixantrone and rituximab is currently under investigation as a second-line treatment for patients ineligible for stem cell transplantation, while pixantrone monotherapy is the only therapeutic option approved for multiply relapsed and refractory DLBCL beyond the second line at this time.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>30280924</pmid><doi>10.2217/fon-2018-0388</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2019-01, Vol.15 (3), p.305-317 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2116125830 |
| source | MEDLINE; PubMed Central |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Canellos, George CAR-T cells Chemotherapy Clinical trials Combined Modality Therapy diffuse large B-cell lymphoma Gene expression Humans ibrutinib Immunotherapy, Adoptive Isoquinolines - therapeutic use Leukemia Lymphoma Lymphoma, Large B-Cell, Diffuse - pathology Lymphoma, Large B-Cell, Diffuse - therapy Lymphoma, Non-Hodgkin - pathology Lymphoma, Non-Hodgkin - therapy Medical imaging Medical prognosis Monoclonal antibodies Participation Patients pixantrone Pyrazoles - therapeutic use Pyrimidines - therapeutic use Rituximab - therapeutic use Salvage Therapy second-line treatment Stem Cell Transplantation Studies Systematic review Targeted cancer therapy Young, Robert |
| title | The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A46%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20rationale%20for%20combination%20therapy%20in%20patients%20with%20aggressive%20B-cell%20non-Hodgkin%20lymphoma:%20ten%20questions&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Jurczak,%20Wojciech&rft.date=2019-01-01&rft.volume=15&rft.issue=3&rft.spage=305&rft.epage=317&rft.pages=305-317&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2018-0388&rft_dat=%3Cproquest_cross%3E2216536462%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216536462&rft_id=info:pmid/30280924&rfr_iscdi=true |